Skip to main content
Equibles
CTTH logo

CTTH · Ctt Pharmaceutical Holdings, Inc.

Track CTTH — free

Use CTTH with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research CTTH.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.06 0.00 (-0.17%) At close · Oct 16
Rebalance outlook locked
Going-concern doubt — flagged Sep 17, 2026

Substantial doubt about the company's ability to continue as a going concern.

“These conditions raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date of issuance of the audited financial statements.”
View the 10-Q filed Sep 17, 2026
Market Cap
$3.52M
Shares
59.72M
Volume · Oct 16 2999 Avg daily vol (3M) 43.28K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.06 Open$0.05 Day$0.05–0.06 52W close$0.04–0.10 Avg vol 30d29K Short int18K · 0.0% float · 1.0d Short vol33% DataJan 2020–Oct 2026 Filing10-Q · Sep 17

Up next

Latest filing: 10-Q
filed Sep 17, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$1.67M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
2.0
Trailing earnings · reciprocal yield 50.9%
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$31
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+35.2%
Year over year · more shares
Price change (1Y)
-29.3%
Trailing year
Short interest
0.0%
Latest settlement · 1.0 days to cover
View all 122 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Neutral Momentum Weak Sentiment Neutral Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 17.3 · elevated Equity put/call 0.56
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg −11%
below
Price vs 50-day avg +4%
above
RSI (14) 59
neutral
MACD trend Positive
52-week position 32%
mid-range
Volume (OBV) Bearish div.
distributing
Momentum
relative strength
Weak
1-month return +21%
trailing
6-month return −20%
trailing
YTD return −2%
this year
Relative strength −27%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow Flat
No 13F holder data
Insider flow Accumulating
Net +$4.3K over 90 days · 0% sells
Short interest Rising
0.03% of float · ▲ +75.6% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
No 13F holder history
Squeeze score 29
low risk · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 166%
annualized · 1-yr
Max drawdown −55%
past year
ATR 11.4%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
2 · 3 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−11% Bearish
Price vs 50-day avg
+4% Bullish
RSI (14)
59 Neutral
MACD trend
Positive Bullish
52-week position
32% Neutral
Volume (OBV)
Bearish div. Bearish
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow Flat
No 13F holder data
Insider flow Accumulating
Net +$4.3K over 90 days · 0% sells
Short interest Rising
0.03% of float · ▲ +75.6% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
No 13F holder history
Price context
position in its 52-week range
Range low $0 Now $0 · 32% Range high $0
vs 200-day avg -11% vs 50-day avg +4%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.

Versus peers

Drug Manufacturers - Specialty & Generic — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
CTTH
Ctt Pharmaceutical Holdings, Inc.
this stock
$3.52M -2.0% — — 0.0%
TAK
Takeda Pharmaceutical Co Ltd
 $64.15B +28.8% — — 0.1%
GALDY
Galderma Group AG/ADR
 $48.88B +2.4% — — 0.0%
TEVA
Teva Pharmaceutical Industries Ltd
 $46.21B +30.9% +4.3% 65.0 2.6%
HLN
Haleon plc
 $44.72B +0.6% — — 0.6%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Short & Settlement
Short Interest Rising
Shares short
18.3K
Days to cover
1.0d
Change
+7.9K sh
View
Short Volume
Short vol %
33%
As of
Oct 16, 2026
Short Total
View
Fails to Deliver
FTD shares
2.2K
Value
$151
As of
Aug 12, 2026
View
Off-Exchange
Off-exchange %
98.0%
Week of
Sep 14, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net buying
Net (90d)
+$4.3K
Buyers / Sellers
1 / 0
Buyers Sellers
View
Financials
Financials
Net income (FY)
$-672.2K
EPS diluted
$0.01
View
Filings
SEC Filings
Latest
8-K
Filed
Oct 9, 2026
This year
11

Holt & Patterson, LLC, CTT Pharmaceutical Holdings, Inc.'s predecessor independent registered public accounting firm, agreed with the company's October 2, 2026 disclosure concerning its change of certifying accountant.

View

Performance

5D 20D 120D MTD YTD
CTTH +7.1% +21.4% -20.4% +3.3% -2.0%
SPY -2.0% +0.2% +6.7% +0.1% +11.9%
vs SPY +9.1% +21.2% -27.1% +3.3% -13.9%
Key facts CIK 1035422 CUSIP 12651E106 Visit website